AustralieFrV1, Main, Exploration, bibRecord, 000A17

Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients.

Identifieur interne : 000A17 ( Main/Exploration ); précédent : 000A16; suivant : 000A18

Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients.

Auteurs : Claire Roger [Australie] ; Menino O. Cotta [Australie] ; Laurent Muller [France] ; Steven C. Wallis [Australie] ; Jeffrey Lipman [Australie] ; Jean-Yves Lefrant [France] ; Jason A. Roberts [Australie]

Source :

International journal of antimicrobial agents [ 1872-7913 ] ; 2017.

RBID : pubmed:28689876

Abstract

This prospective pharmacokinetic study aimed to compare the clearance of piperacillin-tazobactam administered as a 24-h continuous infusion between continuous venovenous haemodiafiltration (CVVHDF) and continuous venovenous haemofiltration (CVVH) applied at equal dose in critically ill patients. A loading dose of 4.5 g of piperacillin-tazobactam followed by a continuous infusion (500 mg/h) was administered to patients randomized to receive CVVHDF or CVVH. Serial pre- and postfilter blood samples were drawn during an 8-h sampling interval. Piperacillin plasma concentrations were measured using a validated chromatography method. Piperacillin pharmacokinetics were calculated using a non-compartmental approach. In total, 212 piperacillin plasma concentrations were determined. Median [interquartile range (IQR)] total piperacillin clearance was 7.5 (5.9-11.2) L/h in the CVVHDF group and 4.7 (4.5-9.6) L/h in the CVVH group (P = 0.21). Median (IQR) piperacillin clearance related to continuous renal replacement therapy (CRRT) was 3.0 (2.7-3.2) L/h in the CVVHDF group and 2.6 (1.9-3.0) L/h in the CVVH group (P = 0.29). Mean (standard deviation) steady state concentrations were 68.4 (25.8) mg/L in the CVVHDF group and 89.1 (35.6) mg/L in the CVVH group (P = 0.16). The estimated unbound concentrations resulting from piperacillin continuous infusion were above the target susceptibility breakpoint (16 mg/L) for the entire dosing interval (100% fT>MIC) in all study patients. In the present study, higher (but not significantly) piperacillin clearance and lower piperacillin exposure were observed in patients receiving CVVHDF compared with CVVH. In patients receiving CRRT, the use of piperacillin continuous infusion should be considered to ensure optimal exposure for less susceptible pathogens.

DOI: 10.1016/j.ijantimicag.2017.03.018
PubMed: 28689876

Affiliations:

Australie, France

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients.</title>
<author><name sortKey="Roger, Claire" sort="Roger, Claire" uniqKey="Roger C" first="Claire" last="Roger">Claire Roger</name>
<affiliation wicri:level="1"><nlm:affiliation>Service des réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, France; Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia. Electronic address: claire.roger@chu-nimes.fr.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Service des réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, France; Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cotta, Menino O" sort="Cotta, Menino O" uniqKey="Cotta M" first="Menino O" last="Cotta">Menino O. Cotta</name>
<affiliation wicri:level="1"><nlm:affiliation>Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia; School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia; Pharmacy Department, Royal Brisbane and Womens' Hospital, Brisbane, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia; School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia; Pharmacy Department, Royal Brisbane and Womens' Hospital, Brisbane, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Muller, Laurent" sort="Muller, Laurent" uniqKey="Muller L" first="Laurent" last="Muller">Laurent Muller</name>
<affiliation wicri:level="1"><nlm:affiliation>Service des réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service des réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes</wicri:regionArea>
<wicri:noRegion>CHU Nîmes</wicri:noRegion>
<wicri:noRegion>CHU Nîmes</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wallis, Steven C" sort="Wallis, Steven C" uniqKey="Wallis S" first="Steven C" last="Wallis">Steven C. Wallis</name>
<affiliation wicri:level="1"><nlm:affiliation>Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lipman, Jeffrey" sort="Lipman, Jeffrey" uniqKey="Lipman J" first="Jeffrey" last="Lipman">Jeffrey Lipman</name>
<affiliation wicri:level="1"><nlm:affiliation>Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia; School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia; Department of Intensive Care Medicine, Royal Brisbane and Womens' Hospital, Brisbane, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia; School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia; Department of Intensive Care Medicine, Royal Brisbane and Womens' Hospital, Brisbane, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lefrant, Jean Yves" sort="Lefrant, Jean Yves" uniqKey="Lefrant J" first="Jean-Yves" last="Lefrant">Jean-Yves Lefrant</name>
<affiliation wicri:level="1"><nlm:affiliation>Service des réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service des réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes</wicri:regionArea>
<wicri:noRegion>CHU Nîmes</wicri:noRegion>
<wicri:noRegion>CHU Nîmes</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Roberts, Jason A" sort="Roberts, Jason A" uniqKey="Roberts J" first="Jason A" last="Roberts">Jason A. Roberts</name>
<affiliation wicri:level="1"><nlm:affiliation>Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia; School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia; Department of Intensive Care Medicine, Royal Brisbane and Womens' Hospital, Brisbane, Queensland, Australia; Pharmacy Department, Royal Brisbane and Womens' Hospital, Brisbane, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia; School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia; Department of Intensive Care Medicine, Royal Brisbane and Womens' Hospital, Brisbane, Queensland, Australia; Pharmacy Department, Royal Brisbane and Womens' Hospital, Brisbane, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28689876</idno>
<idno type="pmid">28689876</idno>
<idno type="doi">10.1016/j.ijantimicag.2017.03.018</idno>
<idno type="wicri:Area/PubMed/Corpus">000727</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000727</idno>
<idno type="wicri:Area/PubMed/Curation">000724</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000724</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000724</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000724</idno>
<idno type="wicri:Area/Ncbi/Merge">004A93</idno>
<idno type="wicri:Area/Ncbi/Curation">004A93</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004A93</idno>
<idno type="wicri:Area/Main/Merge">000A12</idno>
<idno type="wicri:Area/Main/Curation">000A17</idno>
<idno type="wicri:Area/Main/Exploration">000A17</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients.</title>
<author><name sortKey="Roger, Claire" sort="Roger, Claire" uniqKey="Roger C" first="Claire" last="Roger">Claire Roger</name>
<affiliation wicri:level="1"><nlm:affiliation>Service des réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, France; Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia. Electronic address: claire.roger@chu-nimes.fr.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Service des réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, France; Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cotta, Menino O" sort="Cotta, Menino O" uniqKey="Cotta M" first="Menino O" last="Cotta">Menino O. Cotta</name>
<affiliation wicri:level="1"><nlm:affiliation>Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia; School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia; Pharmacy Department, Royal Brisbane and Womens' Hospital, Brisbane, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia; School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia; Pharmacy Department, Royal Brisbane and Womens' Hospital, Brisbane, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Muller, Laurent" sort="Muller, Laurent" uniqKey="Muller L" first="Laurent" last="Muller">Laurent Muller</name>
<affiliation wicri:level="1"><nlm:affiliation>Service des réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service des réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes</wicri:regionArea>
<wicri:noRegion>CHU Nîmes</wicri:noRegion>
<wicri:noRegion>CHU Nîmes</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wallis, Steven C" sort="Wallis, Steven C" uniqKey="Wallis S" first="Steven C" last="Wallis">Steven C. Wallis</name>
<affiliation wicri:level="1"><nlm:affiliation>Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lipman, Jeffrey" sort="Lipman, Jeffrey" uniqKey="Lipman J" first="Jeffrey" last="Lipman">Jeffrey Lipman</name>
<affiliation wicri:level="1"><nlm:affiliation>Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia; School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia; Department of Intensive Care Medicine, Royal Brisbane and Womens' Hospital, Brisbane, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia; School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia; Department of Intensive Care Medicine, Royal Brisbane and Womens' Hospital, Brisbane, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lefrant, Jean Yves" sort="Lefrant, Jean Yves" uniqKey="Lefrant J" first="Jean-Yves" last="Lefrant">Jean-Yves Lefrant</name>
<affiliation wicri:level="1"><nlm:affiliation>Service des réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service des réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes</wicri:regionArea>
<wicri:noRegion>CHU Nîmes</wicri:noRegion>
<wicri:noRegion>CHU Nîmes</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Roberts, Jason A" sort="Roberts, Jason A" uniqKey="Roberts J" first="Jason A" last="Roberts">Jason A. Roberts</name>
<affiliation wicri:level="1"><nlm:affiliation>Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia; School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia; Department of Intensive Care Medicine, Royal Brisbane and Womens' Hospital, Brisbane, Queensland, Australia; Pharmacy Department, Royal Brisbane and Womens' Hospital, Brisbane, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia; School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia; Department of Intensive Care Medicine, Royal Brisbane and Womens' Hospital, Brisbane, Queensland, Australia; Pharmacy Department, Royal Brisbane and Womens' Hospital, Brisbane, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">International journal of antimicrobial agents</title>
<idno type="eISSN">1872-7913</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">This prospective pharmacokinetic study aimed to compare the clearance of piperacillin-tazobactam administered as a 24-h continuous infusion between continuous venovenous haemodiafiltration (CVVHDF) and continuous venovenous haemofiltration (CVVH) applied at equal dose in critically ill patients. A loading dose of 4.5 g of piperacillin-tazobactam followed by a continuous infusion (500 mg/h) was administered to patients randomized to receive CVVHDF or CVVH. Serial pre- and postfilter blood samples were drawn during an 8-h sampling interval. Piperacillin plasma concentrations were measured using a validated chromatography method. Piperacillin pharmacokinetics were calculated using a non-compartmental approach. In total, 212 piperacillin plasma concentrations were determined. Median [interquartile range (IQR)] total piperacillin clearance was 7.5 (5.9-11.2) L/h in the CVVHDF group and 4.7 (4.5-9.6) L/h in the CVVH group (P = 0.21). Median (IQR) piperacillin clearance related to continuous renal replacement therapy (CRRT) was 3.0 (2.7-3.2) L/h in the CVVHDF group and 2.6 (1.9-3.0) L/h in the CVVH group (P = 0.29). Mean (standard deviation) steady state concentrations were 68.4 (25.8) mg/L in the CVVHDF group and 89.1 (35.6) mg/L in the CVVH group (P = 0.16). The estimated unbound concentrations resulting from piperacillin continuous infusion were above the target susceptibility breakpoint (16 mg/L) for the entire dosing interval (100% fT>MIC) in all study patients. In the present study, higher (but not significantly) piperacillin clearance and lower piperacillin exposure were observed in patients receiving CVVHDF compared with CVVH. In patients receiving CRRT, the use of piperacillin continuous infusion should be considered to ensure optimal exposure for less susceptible pathogens.</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>France</li>
</country>
</list>
<tree><country name="Australie"><noRegion><name sortKey="Roger, Claire" sort="Roger, Claire" uniqKey="Roger C" first="Claire" last="Roger">Claire Roger</name>
</noRegion>
<name sortKey="Cotta, Menino O" sort="Cotta, Menino O" uniqKey="Cotta M" first="Menino O" last="Cotta">Menino O. Cotta</name>
<name sortKey="Lipman, Jeffrey" sort="Lipman, Jeffrey" uniqKey="Lipman J" first="Jeffrey" last="Lipman">Jeffrey Lipman</name>
<name sortKey="Roberts, Jason A" sort="Roberts, Jason A" uniqKey="Roberts J" first="Jason A" last="Roberts">Jason A. Roberts</name>
<name sortKey="Wallis, Steven C" sort="Wallis, Steven C" uniqKey="Wallis S" first="Steven C" last="Wallis">Steven C. Wallis</name>
</country>
<country name="France"><noRegion><name sortKey="Muller, Laurent" sort="Muller, Laurent" uniqKey="Muller L" first="Laurent" last="Muller">Laurent Muller</name>
</noRegion>
<name sortKey="Lefrant, Jean Yves" sort="Lefrant, Jean Yves" uniqKey="Lefrant J" first="Jean-Yves" last="Lefrant">Jean-Yves Lefrant</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A17 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A17 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:28689876
   |texte=   Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:28689876" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

Serveur d'exploration sur les relations entre la France et l'Australie

Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients.

Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients.

Source :

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.